Thank you, Tom.
to and cancer. We we able combining proceed necessary XXX-milligram today, some pancreatic dosing that I to study We and start safety in Ib. metastatic the in have the one Ampligen. cover and with to to our need pancreas treatment safe, failures, deemed was were a with least at durvalumab the efficacy there of dose-limiting toxicity announced Ampligen I/II will is a DURIPANC data patient dose additional XXX-milligram determine cancer. Phase gather to Phase recently be to screen of will of bit and encountered The programs AstraZeneca's to complete last-minute trial the the enrolled
the expect adverse far, track the to Thus and on Phase year. we a enrolled be final transition either been X. XXX-milligram the doses have at to or events XXX by there of the calendar no for is smooth end study patient The serious
reported we the assessment. time reach the of stable to X-month cohorts in dose X had X yet the have cohort and X-month the earlier, at higher As the patients low-dose point disease
that this at disease time XX% time and have evaluation historical of a point. both of X the at However, has does of include XXX-milligram the and that's large the historical has point. disease reached dosing, X-month comparably that XXX- time only patients cohort patients X-month Erasmus X evaluable data stable point the patients, X of XX% and have stable
saying standard few of by the approaching X these only The a that time-to-event assessment the pan utilizing Ampligen the to are few X first patients cohort next have progression-free analysis. of which of still X and progression-free has months data And current survival months Kaplan-Meier from historical to The patients evaluating start of door XX XXX-milligram disease. caveat When I data survival months is this the are these and in EAP over compared compare stable weeks alone, from the combination DURIPANC controls. XX FOLFIRINOX preliminary and our with patients. the from X-month
X and gemcitabine standard paclitaxel X approximately of in progression-free care that was survival the durvalumab. improvements FOLFIRINOX alone These survival progression-free of To and context, improvement when metastatic are as in cancer, replaced the Ampligen months. put with in AstraZeneca's months of combination with the pancreas Ampligen X months in the
anxiously occurring last XXXX. We evaluation patient await are enrollment in we for dose-limiting formal of launch which toxicity data by the we and QX encouraged II, these anticipate the the the and Phase
a submitted the advanced FDA, Ampligen the as maintenance for involving protocol the to FDA cancer, the trial discussion therapy edited with for pancreatic and Concerning we the have AMP-XXX comments according October. to we locally our protocol in
we protocol mandatory, and process. clinicaltrials.gov this enrollment days the awaiting time, not At we has updated, allow to IRB FDA protocol been for the are comments. approval to While XX new has disseminating customary to received the sites were begin the
these chemo protocol accelerate site and patients the the stated radiotherapy addition to we and of arms inclusion before, recruitment. patient believe treatment for expands As this and arms criteria treatment I will receiving allow those
I under new further anticipate am protocol of that to new design. concerning hesitant this as there first protocol be forecast current with to the patient sites enrollment will I related negotiations budgets
this list to a motion of and compiled In addition, few for institutions targeted the in have be we full recruitment, site reengage all with expect within of next to weeks. we
Ampligen for the cancer. Regarding ovarian treatment of
level for of wrapped and recurrent early. with cancer advanced in discussed Ampligen, allow last from has treatment by manuscript is patients calendar enrollment containing vaccine the Phase first awaiting is up In combining we the submit trial wrapping cisplatin convinced thus to of the XX. combining open Burke hope far cell and that are Edward the review recruitment call, the he Dr. As of the to so response and of tumor ] be end XX a trial CKM the being the II lymphocytes for with data and to patient [ cancer year. ovarian recurrent They and for the collected earnings enrollment. up a dendritic rate advanced infiltrating to peer was study downsized highlighting ovarian impressed the Ampligen cisplatin the pembrolizumab
the trial this trial exploratory the our report the post-COVID information. scientists biomarker Phase determine greater in and be and how findings for complete condition there of diseased patients, best how the and Concerning received, clinicaltrials.gov data posted has The data fit of for end final data II these utilize has very into with interesting by the and disease we conversations approved the to fatigue, been healthy groups to been advocacy study November. other will and are understanding the are and engaged of between
it like modulates maturation, are proteins. Squares time-consuming addition, nature population clear over data predictive is that mediated best is distinct the is use algorithms populations we to optimal immune target these pertaining there [ still We've to process that patients, others, how the In to as and we ] identify responders. utilized parse clear component cell enrollment. determining Lease analysis with complement we through It different machine among the the biomarkers of and still principal data. certain This are of pathways working X,XXX Ampligen and investigated learning for biomarkers are a to differentials to
Bethesda. the invited meeting was campus in at RECOVER TLC COVID the I long treating attend NIH addition, kickoff to In that's
RECOVER public as was the partners of strategies funding lay treatments the as with and for groundwork It treatment the wonderful long are and to opportunity a COVID. failures and the program. opportunity original design discuss well a private wonderful network next that and to of successes in for interested to
submission many has for of TLC potential portal part the As this therapeutics initiative. be be aware, as launched of tested may RECOVER a program to
trials as treatment for AIM consultation clinical other long the COVID. have to be the clinical would Ampligen We included with a candidate would, and of in and partners assume their chosen, if the of pathway regulatory cost drive with NIH and and the submitted Ampligen
hopeful program. Ampligen in to be that included will We are this ultimately chosen be
switch I'd to like minute. focus Now for a
identify always and and an exploit more better, possible Ampligen the desirable to in diseases treatment the clinical for testing inefficiencies and also to behind any partnerships focus AIM buyouts. we the are where calls product trials tend make of is disorders, and these scenes a Ampligen potential While presentations to working on
be felt Pharma that [indiscernible] spent are individual would AIM manufacturing the and since to improved To manufacturing money. polymer have the streamline joined could shortened, which past production the we the poly blocks with which in Ampligen. the Solutions, and partner is building United optimize Kingdom our Sterling end, the of that potentially working year that and I've save process I ultimately of
also upfront steps an while of all the of combined science yield. Through the And $XXX,XXX chemicals creativity have by But utilize this approximately been XX%. of able and the quality R&D established release is polymer that minor over the production time and loss shortening with little experiments certain investment specifications. hazardous still meeting we a and a to importantly, AIM Sterling in teams of processing remove
should while to with Sterling to ongoing optimization discuss future I'll an estimated This million company about Tom and by in method $X the back financials. total now process it of for Ampligen. costs save also each transfer And batch reducing $XXX,XXX the AIM hand validation
